One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Women in urology � closing the gap
doi : 10.1038/s41585-023-00777-4
Volume 20 Issue 7, July 2023
What can urology learn about sponsorship from business and medicine?
Simone Thavaseelan, Jay D. Raman & Margaret PearleÂ
The past, present and future of women in the United States urological workforce
Catherine S. Nam, Amy N. Luckenbaugh & Akanksha MehtaÂ
Successful mentorship for women in urology � a new era
Anne M. Suskind & Stacy TanakaÂ
Allyship for women in urology
Shree Agrawal-Patel, Smita De, Anna Zampini, Samuel C. Haywood & Eric A. KleinÂ
The value of women urologists � individual and institutional imperatives to address salary equity
Madeline Cancian & Simone ThavaseelanÂ
Gender differences in burnout among urologists
Tiffany L. Damm & M. Francesca MonnÂ
Pregnancy and parental leave in medicine and academia � a focus on urology
Chloe E. Peters & Siobhan M. HartiganÂ
Abortion is a urology workforce issue
Anne P. Cameron & Casey A. SeidemanÂ
Working harder for less � under-represented in medicine women in academic and clinical urology
Efe Chantal Ghanney Simons & Oluwarotimi S. NetteyÂ
Circulating and urinary tumour DNA in urothelial carcinoma � upper tract, lower tract and metastatic disease
Kyle M. Rose, Heather L. Huelster, Joshua J. Meeks, Bishoy M. Faltas, Guru P. Sonpavde, Seth P. Lerner, Jeffrey S. Ross, Philippe E. Spiess, G. Daniel Grass, Rohit K. Jain, Ashish M. Kamat, Aram Vosoughi, Liang Wang, Xuefeng Wang & Roger LiÂ
Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment
Kyle Nolla, David J. Benjamin & David CellaÂ
doi : 10.1038/s41585-023-00747-w
Over the past 5 years, several new immunotherapy treatments have been tested for metastatic renal cell carcinoma (mRCC). Clinical trials assessing combinations of different immunotherapies, or of an immunotherapy with a tyrosine kinase inhibitor (TKI), have reported improved clinical outcomes compared with the standard of care � that is, treatments using TKIs alone.
Genetic control of typical and atypical sex development
Alejandra P. Reyes, Nayla Y. León, Emily R. Frost & Vincent R. HarleyÂ
doi : 10.1038/s41585-023-00754-x
Sex development relies on the sex-specific action of gene networks to differentiate the bipotential gonads of the growing fetus into testis or ovaries, followed by the differentiation of internal and external genitalia depending on the presence or absence of hormones.
Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma � upper tract, lower tract and metastatic disease
Kyle M. Rose, Heather L. Huelster, Joshua J. Meeks, Bishoy M. Faltas, Guru P. Sonpavde, Seth P. Lerner, Jeffrey S. Ross, Philippe E. Spiess, G. Daniel Grass, Rohit K. Jain, Ashish M. Kamat, Aram Vosoughi, Liang Wang, Xuefeng Wang & Roger LiÂ
